Bio-Techne price target lowered to $65 from $90 at Argus

Argus lowered the firm’s price target on Bio-Techne (TECH) to $65 from $90 but keeps a Buy rating on the shares. Bio-Techne’s endmarkets have improved, but it now faces multiple headwinds in the form of trade tariffs and cuts in funding to academic and government customers, the analyst tells investors in a research note. Given the changing dynamics for tariffs and NIH funding however, these headwinds may well be temporary and the improving end markets may be more sustainable, the firm added.